Sanofi Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Belen Garijo Lopez

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Aug 06

Sanofi: How I Leveraged This Undervalued Dividend Aristocrat

Summary Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with a €25B 2030 sales target, but faces biosimilar risk post-2031 and a significant lawsuit threat. New pharma launches and pipeline assets are expected to offset legacy declines, targeting €10B in 2030 sales and with possible margin expansion toward 40%. I implement a bull call spread strategy, targeting ~100% return with the stock 28%-29% higher, but limit position size due to Dupixent litigation. Read the full article on Seeking Alpha

CEO

Belen Garijo Lopez (66 yo)

less than a year

Permanencia

Mrs. Belén Garijo López, M.D., is Director at sanofi since April 29, 2026 and serves as its Chief Executive Officer since May 01, 2026. She was Chair of Executive Board and Chief Executive Officer of Merck...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Belen Garijo Lopez	CEO & Director	less than a year	sin datos	sin datos
François-Xavier Roger	Executive VP & CFO	2.4yrs	sin datos	sin datos
Michael Quigley	Chief Scientific Officer & Head of Research	no data	sin datos	sin datos
Thomas Larsen	Head of Investor Relations & General Medicines	2.7yrs	sin datos	sin datos
Jamie Haney	Executive VP & General Counsel	no data	sin datos	sin datos
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	22.1yrs	sin datos	sin datos
Veronique Jaillet	Executive VP & Interim Chief People Officer	less than a year	sin datos	sin datos
Fabrizio Gaudi	Head of Austrian	7.7yrs	sin datos	sin datos
Erik Wallström	Head of Therapeutic Area - Neurology Development	no data	sin datos	sin datos
Thomas Triomphe	Executive Vice President of Vaccines	8.7yrs	sin datos	sin datos
Karin Knobe	TA Head of Rare Diseases & Rare Blood Disorders Development	no data	sin datos	sin datos
Pablo Sardi	TA Head of Rare & Neurologic Diseases Research	no data	sin datos	sin datos

2.5yrs

Permanencia media

64yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SNY se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Belen Garijo Lopez	CEO & Director	less than a year	sin datos	sin datos
Jean-François Dehecq	Honorary Chairman	16.3yrs	€4.71m	sin datos
Serge Weinberg	Honorary Chairman	3.3yrs	€324.96k	sin datos
Lise Kingo	Independent Director	6.4yrs	€162.00k	0.000080% $ 82.8k
Frederic Oudea	Independent Chairman	3.3yrs	€884.84k	0.000080% $ 82.8k
Rachel Duan	Independent Director	6.4yrs	€151.00k	0.000080% $ 82.8k
Carole Ferrand	Independent Director	4.3yrs	€208.75k	0.000080% $ 82.8k
Barbara Lavernos	Director	5.4yrs	€162.00k	0.000080% $ 82.8k
Clotilde Delbos	Independent Director	2.4yrs	€197.75k	0.000080% $ 82.8k
Emile Voest	Independent Director	4.3yrs	€186.75k	0.000080% $ 82.8k
Christophe Babule	Director	7.6yrs	€156.50k	0.000080% $ 82.8k
Wolfgang Laux	Employee Representative Director	5.4yrs	€129.00k	sin datos

4.9yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de SNY se considera experimentada (4.9 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/09/09 12:53
Precio de las acciones al final del día	2026/09/09 00:00
Beneficios	2026/06/30
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Sanofi está cubierta por 52 analistas. 22 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Sanofi Announces Management Changes

Sanofi Announces Board and Committee Changes

Sanofi, Annual General Meeting, Apr 29, 2026

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Recent updates

Sanofi Shuts Down RSV Vaccine Clinical Trial For Infants And Toddlers After Infant Death

Sanofi: How I Leveraged This Undervalued Dividend Aristocrat

Sanofi Receives European Commission Approval For MenQuadfi Extension To Infants From Six Weeks Of Age Against Invasive Meningococcal Disease

Sanofi Reports Impairment of Intangible Assets for the Second Quarter Ended June 30, 2026

Sanofi to Report Q1, 2027 Results on Apr 23, 2027

Sanofi to Report Q2, 2027 Results on Jul 29, 2027

Sanofi Discontinues Clinical Development of Amlitelimab in Atopic Dermatitis

Sanofi Announces Management Changes

Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector

Sanofi Nexviazyme Meets All Primary and Secondary Endpoints in Infantile-Onset Pompe Disease Phase 3 Study

Sanofi Receives European Commission Approval For Cenrifki (Tolebrutinib) As The First Disability-Targeting Medicine For Secondary Progressive Multiple Sclerosis Without Relapses

Sanofi Receives Approval for Sarclisa Subcutaneous Formulation in Japan for Multiple Myeloma

Sanofi Receives Accelerated Approval for Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes

Sanofi Provides Update On Mobilize Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy

Sanofi Receives European Commission Approval For Sarclisa Subcutaneous As First Anticancer Treatment Administered Via On-Body Injector

The US Food and Drug Administration Accepts Sanofi’s venglustat for priority review in the US to treat type 3 Gaucher disease

Sanofi Demonstrates Superiority Of Efdoralprin Alfa Over Standard-Of-Care Augmentation Therapy In Achieving Higher Functional Alpha-1 Antitrypsin Levels In Alpha-1 Antitrypsin Deficiency

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Announces Board and Committee Changes

Sanofi Approves Ordinary Annual Dividend, Payable on May 7, 2026

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike in Head-To-Head Study

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada

Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP

Sanofi Announces EU Approval of Rezurock for Treatment of Chronic Graft-Versus-Host Disease

Sanofi Presents New Results from Amlitelimab Phase 3 Studies in Atopic Dermatitis

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

Sanofi Earns Breakthrough Therapy Designation in the Us for Venglustat for Type 3 Gaucher Disease

Sanofi, Annual General Meeting, Apr 29, 2026

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes

Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study

Sanofi Announces New Data from the Alphamedix-02 Phase 2 Study Evaluating Alphamedix

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi's Tzield Accepts for Expanded Review in the US for Stage 3 Type 1 Diabetes Through FDA Commission's National Priority Voucher Pilot Program

Sanofi's High-Dose Influenza Vaccine Demonstrates Superior Protection for Older Adults Against Hospitalization vs Standard-Dose

Sanofi Provides Update on Regulatory Review in the EU for Rezurock to Treat Chronic Graft-Vs-Host Disease

Sanofi's Wayrilz Recommends for Eu Approval by the CHMP to Treat Immune Thrombocytopenia

Sanofi Announces Positive Results from the ALPHAMEDIX-02 Phase 2 Study

Sanofi to Report Q3, 2026 Results on Oct 30, 2026

Sanofi Expands Patient Affordable Program by Offering Access to All Its Insulins for $35 Per Month in the US

Sanofi Announces its SAR446268 Receives US Fast Track Designation for Treatment of Non-Congenital Myotonic Dystrophy Type 1

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Steriles Manufacturing Site in Ridgefield, New Jersey of Sanofi (ENXTPA:SAN).

Sanofi Announces the Us Food and Drug Administration Approves Wayrilz (Rilzabrutinib) in US as First BTK Inhibitor for Immune Thrombocytopenia

Sanofi Confirms Earnings Guidance for the Year 2025

Sanofi's Sarclisa Approves in the EU for the Treatment of Transplant-Efficient Newly Diagnosed Multiple Myeloma

Sanofi Announces BEYFORTUS Reduced Hospital and Doctor Visits for RSV Disease in Babies by 87%

Sanofi (ENXTPA:SAN) entered into an agreement to acquire Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC for $1.6 billion.